Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.03.09.21253183: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: 26 Ethics: This study was approved by the NCGM ethics review board (NCGM-G-003494-0). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The most important limitation of this study is its retrospective cohort design. We attempted to adjust various factors that affect clinical outcomes; …
SciScore for 10.1101/2021.03.09.21253183: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: 26 Ethics: This study was approved by the NCGM ethics review board (NCGM-G-003494-0). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The most important limitation of this study is its retrospective cohort design. We attempted to adjust various factors that affect clinical outcomes; however, our method does not enable us to adjust all confounding factors.14,31 In particular, the difference in LoS between the two study groups should be considered carefully for reasons noted above. In addition, because our data are derived from a registry, several items are difficult to interpret. For example, fatality in this study means a patient died during hospitalisation. Even if a patient died after discharge, we categorised the patient as survived. The cause of death is also not available from registry data, and therefore, we cannot determine the cause of death in patients with serious comorbidities such as cancer. Although patients who were hospitalised and/or administered remdesivir in the late clinical course were excluded from the study, a fraction may have been administered remdesivir during or after initiation of IMV/ECMO. Therefore, the risk of IMV/ECMO may be overestimated in the case group. Furthermore, COVIREGI-JP does not collect information on the daily clinical status of each patient. It was difficult to match time-dependent factors such as severity on each day between the case and control groups using the available data. Therefore, bias may have impacted our results to some extent, even using matched data. Adverse events attributable to remdesivir were determined by researchers and may have been underrepo...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-